AnaCardio
Phase 2AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
Founded
2017
Focus
Small Molecules
About
AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
Funding History
2Total raised: $12.5M
Series A$10MIndustrifondenSep 15, 2023
Seed$2.5MKurma PartnersJun 15, 2022
Company Info
TypePrivate
Founded2017
LocationStockholm, Sweden
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile